US EditionNovartis Opens Second Biotech Facility in Austria
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Novartis Opens Second Biotech Facility in Austria
The pharmaceutical company Novartis has commissioned its second state-of-the-art cell culture facility for the production of monoclonal antibodies in Kundl (Kufstein district). The opening of the facility, which has been invested in with a total of €500 million, along with its sister facility in Schaftenau (Kufstein district), which opened in June 2024, is seen as a strong signal for the Austrian life sciences sector. With this expansion, Novart…
After that in Schaftenau, Novartis now opened a 250 million euro production plant for antibody proteins in Kundl. Pharmaceutical company leaders criticize inflation, high costs and bureaucracy in Austria as well as general conditions in Europe.
The pharmaceutical company Novartis opened the second cell culture plant for monoclonal antibodies in Kundl (Kufstein district) on Monday. The commissioning of the "sister plant" in Schaftenau (Kufstein district) had already taken place in June 2024. Novartis has invested 500 million euros in the new biotech plants - half of them split. At the opening ceremony, however, the responsible parties were admonished to have better conditions for the in…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
